Early trials probe COX-2 inhibitors' cancer-fighting potential.
J
J
Ziegler
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000068579:Celecoxib; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D011720:Pyrazoles; D012878:Skin Neoplasms / Q000188:drug therapy; D013449:Sulfonamides / Q000627:therapeutic use*; D013450:Sulfones; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib